SAM #NOI-OD-26-006986

NIH Sole Source Procurement: Miltenyi Biotec GentleMACS Octo Dissociator with Heater

The National Institutes of Health (NIH) Clinical Pharmacology Laboratory is seeking to procure a GentleMACS Octo Dissociator with Heater from Miltenyi Biotec, Inc. for automated tissue sample processing in support of pharmacokinetic and biomarker studies. - Government Buyer: - National Institutes of Health (NIH) - Clinical Pharmacology Laboratory (CPL) - Clinical Center, Office of Purchasing and Contracts - OEM Highlight: - Miltenyi Biotec, Inc. is the sole specified manufacturer and vendor - Products/Services Requested: - GentleMACS Octo Dissociator with Heater (Generation 3) - Quantity: 1 unit - Purpose: Automated dissociation and homogenization of preclinical and clinical tissue samples prior to LC-MS analysis - Features: Processes up to eight samples simultaneously, includes integrated heating units, and supports standardized protocols - Notable Requirements: - Instrument is critical for translational pharmacology, biomarker discovery, and PK/PD profiling - No installation or training required; delivery included - Sole source justification due to unique capabilities and lack of competition - Acquisition will be conducted under simplified acquisition procedures (FAR Part 13)

Description

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.

This procurement is for a Miltenyi Biotec GentleMACS Octo Dissociator with Heater to be located in the Clinical Pharmacology Laboratory (CPL) at the National Institutes of Health (NIH). The instrument is essential for the automated dissociation and homogenization of preclinical and clinical tissue samples prior to liquid chromatography-mass spectrometry (LC-MS) analysis. These procedures are required for the accurate quantification of therapeutic agents and their metabolites in tissues for pharmacokinetic (PK) and tissue distribution studies.This equipment is integral to the CPL’s role in supporting translational pharmacology, biomarker discovery, and pharmacokinetic/pharmacodynamic (PK/PD) profiling across multiple NIH protocols and collaborations.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to Ryssa.nix@nih.gov by close date.

View original listing